Article
Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event management algorithm in patients treated with adjuvant dabrafenib plus trametinib: Primary results of COMBI-APlus.
European journal of cancer (Oxford, England : 1990) - 1 Mar 2022
Atkinson Victoria, Robert Caroline, Grob Jean J, Gogas Helen, Dutriaux Caroline, Demidov Lev, Gupta Avinash, Menzies Alexander M, Ryll Bettina, Miranda Flora, Banerjee Hiya, Lau Mike, Del Vecchio Michele
Abstract excerpt
BACKGROUND: COMBI-AD demonstrated long-term benefit of adjuvant dabrafenib plus trametinib in patients with resected stage III BRAF V600E/K-mutant melanoma; however, 9% of patients permanently discontinued therapy due to pyrexia. COMBI-APlus evaluated whether an adapted pyrexia management algorithm reduces high-grade pyrexia and pyrexia-related adverse outcomes. METHODS: COMBI-APlus is an open-label, phase IIIb...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.